Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01099774 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 597
- Enrollment target
NCT01099774 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 597 participants.
The verdict
NCT01099774, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 597 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of bimatoprost 0.03% formulation B ophthalmic solution with LUMIGAN® (bimatoprost ophthalmic solution 0.03%) once daily for 12 weeks in patients with glaucoma or ocular hypertension
Interventions
- DRUG Bimatoprost 0.03% Ophthalmic Solution
- DRUG Bimatoprost 0.03% Formulation B Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 597 participants |
| Start Date | 2010-05-01 |
| Est. Completion | 2011-04-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01099774
The ClinicalTrials.gov registry entry for NCT01099774 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 597 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bimatoprost 0.03% Ophthalmic Solution is the first listed.
NCT01099774 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01099774 about?
NCT01099774 is a clinical study titled "Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension". This study will evaluate the safety and efficacy of bimatoprost 0.03% formulation B ophthalmic solution with LUMIGAN® (bimatoprost ophthalmic solution 0.03%) once daily for 12 weeks in patients with glaucoma or ocular hypertension
What is the current status of trial NCT01099774?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 597 participants. The study started on 2010-05-01. Estimated completion is 2011-04-29.
What interventions are being tested in trial NCT01099774?
The interventions under investigation include: Bimatoprost 0.03% Ophthalmic Solution (DRUG), Bimatoprost 0.03% Formulation B Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT01099774?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.